N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane
申请人:Pfizer Inc.
公开号:US04602016A1
公开(公告)日:1986-07-22
N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.